Breaking News Instant updates and real-time market news.

MYL

Mylan

$35.94

-0.9 (-2.44%)

16:51
10/07/16
10/07
16:51
10/07/16
16:51

Mylan agrees to $465M settlement with DOJ on EpiPen Auto-Injector

Mylan N.V.announced that its subsidiary, Mylan has agreed to the terms of a $465 million settlement with the U.S. Department of Justice and other government agencies that will resolve questions that have been raised about the classification of EpiPen Auto-Injector and EpiPen Jr Auto-Injector for purposes of the Medicaid Drug Rebate Program. The terms of the settlement do not provide for any finding of wrongdoing on the part of Mylan or any of its affiliated entities or personnel. The question in the underlying matter was whether EpiPen Auto-Injector was properly classified with the Centers for Medicaid and Medicare Services as a non-innovator drug under the applicable definition in the Medicaid Rebate statute and subject to the formula that is used to calculate rebates to Medicaid for such drugs. EpiPen Auto-Injector has been classified with CMS as a non-innovator drug since before Mylan acquired the product in 2007 based on longstanding written guidance from the federal government. The settlement terms provide for resolution of all potential rebate liability claims by federal and state governments as to whether the product should have been classified as an innovator drug for CMS purposes and subject to a higher rebate formula. In connection with the settlement, Mylan expects to enter into a corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services. Mylan will continue to work with the government to finalize the settlement. Mylan CEO Heather Bresch commented, "This agreement is another important step in Mylan's efforts to move forward and bring resolution to all EpiPen Auto-Injector related matters. The agreement is in addition to the significant steps Mylan has taken in relation to EpiPen Auto-Injector over the past several weeks, including the unprecedented, pending launch of a generic version of EpiPen Auto-Injector and expansion of our patient access programs for this product. Entering into this settlement is the right course of action at this time for the Company, its stakeholders and the Medicaid program." Mylan will include a pre-tax charge of approximately $465 million in the quarter ended Sept. 30, 2016 as a result of this settlement.

  • 07

    Oct

  • 28

    Mar

MYL Mylan
$35.94

-0.9 (-2.44%)

09/22/16
ARGS
09/22/16
NO CHANGE
ARGS
Mylan weakness creates good entry point, says Argus
After Mylan's stock fell 17% over the last month, Argus analyst Jacob Kilstein thinks that the stock has reached an attractive entry point, He says that the company's new generic EpiPen will cannibalize branded sales but should help it beat upcoming generic competitors. He thinks that the stock is undervalued and keeps a Buy rating on the stock.
09/23/16
BERN
09/23/16
NO CHANGE
BERN
Mylan generic Epipen to lower EPS by about 10%, says Bernstein
Bernstein analyst Aaron Gal estimates that Mylan's decision to introduce a generic version of its EpiPen will create a drag of about 10% on its EPS. After viewing the Congressional hearings on the device, Gal continues to believe that a competitor to EpiPen will hit the market before the end of 2018. He keeps a $60 price target and Outperform rating on Mylan.
09/30/16
LEER
09/30/16
NO CHANGE
Target $45
LEER
Outperform
Mylan price target cut to $45 on lower EpiPen estimates at Leerink
Leerink analyst Jason Gerberry lowered his EpiPen sales forecasts by 33-45% from 2017-2021 in light of recent company updates, including its plan to launch an authorized generic of the emergency treatment later this year. While Mylan "appears on the right side of the law" regarding the latest Medicaid rebate controversy, Gerberry believes investors should consider the risk of a future settlement related to the issue. He cut his price target on Mylan shares to $45 from $55, but keeps an Outperform rating on the stock as he sees cash flows being sufficient to justify the current price.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $52
JPMS
Overweight
Mylan price target lowered to $52 from $62 at JPMorgan
JPMorgan analyst Chris Schott lowered his price target for Mylan to $52 saying he remains cautious on the shares over the near-term given the ongoing Epipen controversy. The analyst, however, views the stock as "very inexpensive" and keeps an Overweight rating on the name. Schott sees a limited long-term impact to his thesis from the Epipen controversy and believes Mylan's generics business is underappreciated. He maintains an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

CXP

Columbia Property

$23.01

0.04 (0.17%)

05:40
02/22/17
02/22
05:40
02/22/17
05:40
Upgrade
Columbia Property rating change  »

Columbia Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

DISCA

Discovery

$29.62

0.94 (3.28%)

05:38
02/22/17
02/22
05:38
02/22/17
05:38
Downgrade
Discovery rating change  »

Discovery downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISIL

Intersil

$22.20

0.02 (0.09%)

, RNECY

Renesas

05:38
02/22/17
02/22
05:38
02/22/17
05:38
Hot Stocks
Intersil, Renesas announce regulatory approval for acquisition of Intersil »

Renesas Electronics…

ISIL

Intersil

$22.20

0.02 (0.09%)

RNECY

Renesas

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENTL

Entellus Medical

$17.08

0.06 (0.35%)

05:36
02/22/17
02/22
05:36
02/22/17
05:36
Downgrade
Entellus Medical rating change  »

Entellus Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$16.05

-2.95 (-15.53%)

05:34
02/22/17
02/22
05:34
02/22/17
05:34
Downgrade
Momenta rating change  »

Leerink downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$78.44

0.66 (0.85%)

05:33
02/22/17
02/22
05:33
02/22/17
05:33
Hot Stocks
Bunge forms JV with Bahri, terms not disclosed »

Bahri Dry Bulk, or BDB, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AU

AngloGold

$12.54

-0.36 (-2.79%)

05:30
02/22/17
02/22
05:30
02/22/17
05:30
Downgrade
AngloGold rating change  »

AngloGold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

$31.99

0.5 (1.59%)

05:27
02/22/17
02/22
05:27
02/22/17
05:27
Hot Stocks
Toll Brothers backs FY17 adjusted gross margin »

Toll Brothers reaffirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

STM

STMicroelectronics

$14.64

0.38 (2.66%)

05:27
02/22/17
02/22
05:27
02/22/17
05:27
Upgrade
STMicroelectronics rating change  »

STMicroelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZSEY

Allianz

$17.45

0.13 (0.75%)

05:25
02/22/17
02/22
05:25
02/22/17
05:25
Initiation
Allianz initiated  »

Allianz initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IHG

InterContinental

$48.62

0.42 (0.87%)

05:25
02/22/17
02/22
05:25
02/22/17
05:25
Downgrade
InterContinental rating change  »

InterContinental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUKOY

Lukoil

$55.80

0.87 (1.58%)

05:24
02/22/17
02/22
05:24
02/22/17
05:24
Upgrade
Lukoil rating change  »

Lukoil upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

$31.99

0.5 (1.59%)

05:23
02/22/17
02/22
05:23
02/22/17
05:23
Earnings
Toll Brothers reports Q1 EPS 42c, consensus 35c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

QCOM

Qualcomm

$56.75

0.29 (0.51%)

, CHL

China Mobile

$56.46

0.35 (0.62%)

05:17
02/22/17
02/22
05:17
02/22/17
05:17
Hot Stocks
Qualcomm, China Mobile, ZTE announce collaboration on 5G NR trials »

Qualcomm Technologies, a…

QCOM

Qualcomm

$56.75

0.29 (0.51%)

CHL

China Mobile

$56.46

0.35 (0.62%)

ZTCOY

ZTE Corp.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ECL

Ecolab

$124.03

0.08 (0.06%)

04:58
02/22/17
02/22
04:58
02/22/17
04:58
Downgrade
Ecolab rating change  »

Ecolab downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$61.02

1.79 (3.02%)

, TSN

Tyson Foods

$63.31

-1.95 (-2.99%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
The Consumer Analyst Group of New York to hold a conference »

2017 CAGNY Conference is…

GIS

General Mills

$61.02

1.79 (3.02%)

TSN

Tyson Foods

$63.31

-1.95 (-2.99%)

TWNK

Hostess Brands

$15.47

-0.13 (-0.83%)

MJN

Mead Johnson

$87.47

-0.03 (-0.03%)

K

Kellogg

$74.74

1.84 (2.52%)

MDLZ

Mondelez

$44.97

2.47 (5.81%)

INGR

Ingredion

$122.02

1.23 (1.02%)

LNCE

Snyder's-Lance

$39.38

0.38 (0.97%)

SYY

Sysco

$52.81

0.46 (0.88%)

JNJ

Johnson & Johnson

$119.66

0.8 (0.67%)

SJM

J.M. Smucker

$141.92

5.97 (4.39%)

MO

Altria Group

$73.65

0.68 (0.93%)

CPB

Campbell Soup

$58.95

0.47 (0.80%)

PEP

PepsiCo

$109.36

1.21 (1.12%)

CLX

Clorox

$135.44

1.73 (1.29%)

BG

Bunge

$78.44

0.66 (0.85%)

PG

Procter & Gamble

$91.67

0.58 (0.64%)

DANOY

Danone

$12.92

-0.125 (-0.96%)

SPB

Spectrum Brands

$134.58

0.67 (0.50%)

KO

Coca-Cola

$41.46

0.23 (0.56%)

IFF

International Flavors

$121.62

-0.75 (-0.61%)

STZ

Constellation Brands

$160.09

-1.23 (-0.76%)

NSRGY

Nestle

$72.92

-0.825 (-1.12%)

CHD

Church & Dwight

$49.61

-0.09 (-0.18%)

UN

Unilever; also tag UL

$45.09

-3.7 (-7.58%)

CL

Colgate-Palmolive

$73.18

1.2 (1.67%)

NWL

Newell Brands

$46.49

-0.15 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 24

    Feb

  • 09

    Mar

  • 14

    Mar

  • 15

    Mar

  • 19

    Mar

  • 27

    Mar

  • 09

    May

RIO

Rio Tinto

$44.89

0.65 (1.47%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
Rio Tinto management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 24

    Feb

  • 26

    Feb

CRUS

Cirrus Logic

$55.17

-0.16 (-0.29%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
Cirrus Logic management to meet with Canaccord »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

VWDRY

Vestas

$24.97

0.34 (1.38%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
Vestas management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

MPWR

Monolithic Power

$88.22

1.7 (1.96%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
Monolithic Power management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 04

    Apr

  • 05

    Apr

WEB

Web.com

$20.40

0.2 (0.99%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
Web.com management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

OCLR

Oclaro

$10.97

-0.05 (-0.45%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
Oclaro management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 03

    Mar

HAS

Hasbro

$98.88

0.38 (0.39%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
Hasbro management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

FLWS

1-800-Flowers.com

$10.10

0.1 (1.00%)

04:55
02/22/17
02/22
04:55
02/22/17
04:55
Conference/Events
1-800-Flowers.com management to meet with Benchmark »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

04:55
02/22/17
02/22
04:55
02/22/17
04:55
General news
Breaking General news story  »

FOMC Minutes to be…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.